← brief for 2026-08-11 · Slowing decline

Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This is a large review that combined many studies of GLP-1 drugs, the kind used for diabetes and weight loss, in people whose kidneys have failed. It looked at whether these drugs are safe and helpful for people on dialysis or with end-stage kidney disease. Pooling many studies makes this some of the strongest evidence we have, though it still depends on the trials inside it.

Who did this work

Dutta D · Jena S · Mahajan K · Kamrul-Hasan ABM · Bhattacharya S · Mohindra R

Source

Article · PubMed, the drug frontier · 2026 Aug 4
https://pubmed.ncbi.nlm.nih.gov/42551699/